Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops …

1 day ago · Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 …

CouponFollow Extension

$0.61
OFF

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops …

2 weeks from now

1 day ago · Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 …

yahoo.com

22%
OFF

Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call …

2 weeks from now

19 hours ago · Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and …

yahoo.com

$0.61
OFF

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue ...

2 weeks from now

2 days ago · Tarsus Pharmaceuticals, Inc. (TARS Quick Quote TARS - Free Report) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of …

zacks.com

$0.61
OFF

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops …

2 weeks from now

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year …

msn.com

$0.61
OFF

Tarsus Pharmaceuticals Reports Strong Q3 2024 Performance

2 weeks from now

1 day ago · Tarsus Pharmaceuticals reports Q3 EPS (61c), consensus (94c) TipRanks 13h Tarsus Pharmaceuticals GAAP EPS of -$0.61 beats by $0.31, revenue of $48.1M beats by …

businessinsider.com

18%
OFF

Tarsus Q3 Revenue Jumps 18% To $48.1M As XDEMVY Sales …

2 weeks from now

1 day ago · Tarsus Pharmaceuticals (NASDAQ: TARS) reported Q3 2024 financial results, highlighting $48.1 million in XDEMVY® net product sales, an 18% increase over Q2 2024. The …

stocktitan.net

7%
OFF

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Misses …

2 weeks from now

Nov 9, 2022 · This company is expected to post quarterly loss of $0.20 per share in its upcoming report, which represents a year-over-year change of -185.7%. The consensus EPS estimate …

yahoo.com

$72600
OFF

Tarsus Pharmaceuticals Territory Leader Buffalo Job Buffalo

2 weeks from now

Jul 18, 2024 · Easy 1-Click Apply Tarsus Pharmaceuticals Territory Leader - Buffalo Full-Time ($72,600 - $108,000) job opening hiring now in Buffalo, NY 14266. Apply now!

ziprecruiter.com

82%
OFF

Tarsus Pharmaceuticals, Inc. (TARS) - Yahoo Finance

2 weeks from now

PMVP PMV Pharmaceuticals, Inc. 1.7400. +4.82%. Find the latest Tarsus Pharmaceuticals, Inc. (TARS) stock quote, history, news and other vital information to help you with your stock …

yahoo.com

FAQs about Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops … Coupon?

How much did Tarsus pharmaceuticals (Tars) earn in Q3 2024?

SA Transcripts 150.4KFollowers Follow Q3: 2024-11-13 Earnings Summary Play Call10-Q EPS of -$0.61 beats by $0.31 | Revenue of $48.12M(2,471.78% Y/Y)beats by $4.94M Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET ...

Who is in Tarsus' third quarter 2024 financial results conference call?

Lachlan Hanbury-Brown - William Blair Andrea Newkirk - Goldman Sachs Oren Livnat - HC Wainwright Balaji Prasad - Barclays Jason Gerberry - Bank of America Merrill Lynch Corey Jubinville - Life Sci Capital Francois Brisebois - Oppenheimer Operator Welcome to Tarsus' Third Quarter 2024 Financial Results Conference Call. ...

Is Tarsus Pharmaceuticals stock a Sustainable Stock?

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Tarsus Pharmaceuticals shares have added about 134.9% since the beginning of the year versus the S&P 500's gain of 25.5%. ...

What is Tarsus pharmaceuticals tp-03?

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company’s lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites. ...

How much did P&L cost in the third quarter of 2024?

Turning to our P&L total operating expenses were approximately $73.3 million for the third quarter of 2024 and remained relatively flat, inclusive of the expanded sales force offset by other sales and marketing costs. ...